3 accounting jobs found

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To...

Job Title Sales, Enterprise Client Director (AM&D) – South Region (TN, LA, MS, AL, AR) Job Description Sales, Enterprise Client Director (AM&D) – South Region ( TN, LA, MS, AL, AR) Opportunity to join a collaborative Philips Ambulatory Monitoring and Diagnostics team with a strong internal network that aligns key players to support the delivery of value to our customers in order to execute deals.  This team maximizes the customer experience by creating a predictable process of information gathering and exchange to present an efficient One Philips approach.  Your role: You will be the main point of contact for Ambulatory Monitoring and Diagnostics, partnering with Account Team, using business knowledge, and understanding, to develop and drive regional strategies to grow AM&D portfolio throughout the key IDN systems.  Calling on the C Suite to standardize the IDN with one Philips solution. You will lead development and delivery of customer...

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH.   Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c).   Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration....